All News

2019

October

Media Release / Oct 16, 2019

Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease

Read More
Featured News / Oct 11, 2019

Pride @ Novartis 2019

As a company, we stand up for greater inclusion of LGBTI people because when each of us feels included, we all benefit.

Read More
Media Release / Oct 10, 2019

Novartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis

Read More
Media Release / Oct 09, 2019

Novartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx® in clinical practice

Read More
Christine Hà, blind chef, shares advice on navigating the world as a visually impaired entrepreneur.
Story / Oct 08, 2019

Lessons from a blind chef

Christine Hà lost her vision at a young age – and went on to become an award-winning chef.

Read More
Media Release / Oct 08, 2019

Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg

Read More
Media Release / Oct 08, 2019

Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

Read More
Media Release / Oct 05, 2019

AveXis presents updated STRONG data at WMS

Read More
Lauren Abrey and her two daughters posing in front of a city.
Story / Oct 03, 2019

Women in Science: Lauren Abrey

Learn about the career of our Global Medical Affairs Head for Solid Tumors and Rare Diseases.

Read More
Media Release / Oct 02, 2019

Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More